ADAM17 Deficiency Protects against Pulmonary Emphysema.

Autor: Saad MI; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia., McLeod L; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia., Hodges C; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia., Vlahos R; School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia; and., Rose-John S; Institute of Biochemistry, Christian-Albrechts-University, Kiel, Germany., Ruwanpura S; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia., Jenkins BJ; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.

Publikováno v: American journal of respiratory cell and molecular biology [Am J Respir Cell Mol Biol] 2021 Feb; Vol. 64 (2), pp. 183-195.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

美沙拉嗪对 RAW264.7 细胞中促炎因子和过氧化物的抑制作用 及其对牙周炎模型大鼠的治疗作用.

Autor: 王浩宇¹, 王宇琪¹, 王冰倩¹, 聂瑾涵¹, 闫嘉晴² yjq@mail.jlu.edu.cn, 胡 敏¹ humin@jlu.edu.cn

Publikováno v: Journal of Jilin University (Medicine Edition). Sep2024, Vol. 50 Issue 5, p1250-1258. 9p.

ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.

Autor: Saad MI; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia., Alhayyani S; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia., McLeod L; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia., Yu L; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia., Alanazi M; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia., Deswaerte V; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia., Tang K; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia., Jarde T; Cancer Program, Monash Biomedicine Discovery Institute, Clayton, Vic., Australia.; Department of Anatomy and Developmental Biology, Monash University, Clayton, Vic., Australia.; Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Vic., Australia., Smith JA; Department of Surgery, School of Clinical Sciences at Monash Health, Monash University, Clayton, Vic., Australia.; Department of Cardiothoracic Surgery, Monash Health, Clayton, Vic., Australia., Prodanovic Z; Monash Biobank, Monash Health, Clayton, Vic., Australia., Tate MD; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia., Balic JJ; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia., Watkins DN; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia., Cain JE; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.; Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Vic., Australia., Bozinovski S; School of Health and Biomedical Sciences, RMIT University, Bundoora, Vic., Australia., Algar E; Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Vic., Australia.; Genetics and Molecular Pathology Laboratory, Monash Health, Clayton, Vic., Australia., Kohmoto T; Department of Human Genetics, Tokushima University Graduate School of Medicine, Tokushima, Japan.; Division of Molecular Genetics, Aichi Cancer Center Research Institute, Nagoya, Japan., Ebi H; Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Japan.; Division of Advanced Cancer Therapeutics, Nagoya University Graduate School of Medicine, Nagoya, Japan., Ferlin W; NovImmune SA, Geneva, Switzerland., Garbers C; Department of Pathology, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany., Ruwanpura S; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia., Sagi I; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Rose-John S; Institute of Biochemistry, Christian-Albrechts-University, Kiel, Germany., Jenkins BJ; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia brendan.jenkins@hudson.org.au.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.

Publikováno v: EMBO molecular medicine [EMBO Mol Med] 2019 Apr; Vol. 11 (4).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.